Active Ingredient History
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Carcinoma, Non-Small-Cell Lung (approved 2021)
Adenocarcinoma of Lung (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Colorectal Neoplasms (Phase 3)
Drug Evaluation (Phase 2)
Endometrial Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Hamartoma (Phase 2)
Healthy Volunteers (Phase 1)
Liver Diseases (Phase 1)
Lung Neoplasms (Phase 2)
Mutation (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 1/Phase 2)
Proto-Oncogene Proteins p21(ras) (Phase 2)
ras Proteins (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue